Vaxcyte
PCVX
316 hedge funds and large institutions have $5.88B invested in Vaxcyte in 2025 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 130 increasing their positions, 98 reducing their positions, and 63 closing their positions.
47% more capital inflows, than outflows
Capital inflows: $1.27B | Capital outflows: $867M
44% more call options, than puts
Call options by funds: $14.1M | Put options by funds: $9.8M
33% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 98
3.96% more ownership
Funds ownership: 109.34% → 113.3% (+4%)
8% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 63
2% less funds holding
Funds holding: 324 → 316 (-8)
42% less funds holding in top 10
Funds holding in top 10: 12 → 7 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$280M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$158M |
| 3 |
Janus Henderson Group
London,
|
+$95.2M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$69M |
| 5 |
Deep Track Capital
Greenwich,
Connecticut
|
+$60M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$158M |
| 2 |
Perceptive Advisors
New York
|
-$80.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$46.3M |
| 4 |
BlackRock
New York
|
-$42.1M |
| 5 |
Fred Alger Management
New York
|
-$40M |
PCVX Hedge Fund Activity: Q1 2025 in Review
316 of the 7,483 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2025, worth a combined $5.88B — down 49% from $11.5B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of PCVX and 58 opened new positions — a net loss of 5 holders — while 98 trimmed existing stakes and 130 added.
The largest buyer was RA Capital Management, adding an estimated $280M. The largest seller was Goldman Sachs, cutting an estimated $158M.
- 316 institutional investors held Vaxcyte (PCVX) as of Q1 2025, down from 324 in Q4 2024.
- Funds reported $5.88B of Vaxcyte stock for Q1 2025, down 49% quarter-over-quarter.
- 58 funds opened new Vaxcyte positions in Q1 2025 and 63 closed out, a net change of -5 holders.
- The largest Vaxcyte buyer in Q1 2025 was RA Capital Management, an estimated $280M added.
- The largest Vaxcyte seller in Q1 2025 was Goldman Sachs, an estimated $158M sold.
Based on aggregated 13F filings for Q1 2025.